Public-registry site landscape for NCT07710885, a Biliary Tract Cancer study sponsored by Taiho Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07710885 (registry record) |
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Condition(s) | Biliary Tract Cancer |
| Phase | PHASE3 |
| Listed sites | 21 |
| Site countries | Australia, Japan, South Korea, Thailand |
At National Hospital Organization Kyushu Cancer Center — one of the facilities listed on this trial — 1 other study is actively recruiting Biliary Tract Cancer patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07710885 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →